Passage Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 102.06 million compared to USD 136.13 million a year ago. Basic loss per share from continuing operations was USD 1.86 compared to USD 2.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -1.49% | -10.20% | +30.69% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.69% | 81.33M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023